The Viral Vector & Plasmid DNA Manufacturing Market Size accounted for USD 5.4 Billion in 2023 and is estimated to achieve a ...

Dengue’s rise in 2024, influenced by climate change and shifting serotypes, underscores the need for effective vaccines to ...

The new nasal vaccine only needs one dose and produces reliable immunity right at the site where the virus enters the body.

Intranasal influenza virus-vectored vaccine offers protection against clade 2.3.4.4b H5N1 infection in small animal models. Nature Communications , 2025; 16 (1) DOI: 10.1038/s41467-025-58504-z ...

The company will also present a poster on randomized Phase II data of TG4001 in combination with avelumab in the cervical cancer subgroup. The 2025 American Society of Clinical Oncology (ASCO), annual ...

Vector vaccines use a harmless virus to deliver genetic material into the body to trigger an immune response against the targeted disease. The researchers conducted a review of 70 studies on ...

GEO-CM04S1 Demonstrates Durable T Cell and Antibody Responses in Healthy and Immunocompromised Populations ...

The Problem When COVID-19 emerged in March 2020, Canada’s health care system was confronted with a unique challenge. As emergency rooms swelled with patients, there was intense pressure to come up ...

Recognized Biologics Executive to Oversee Critical Expansion of U.S.-Based Development Capabilities ATLANTA, GA - April 22, ...